Figure 2.

Effect of VEGF-A and angiotensin II treatment on the expression of angiotensin receptors. Bone marrow-derived mesenchymal stem cells (BM-MSCs) were cultured in vascular endothelial growth factor (VEGF-A; 2 ng/ml), angiotensin II (Ang II; 2 ng/ml), or combined VEGF-A/Ang II for 24 hours. Expression of angiotensin receptor AT1R and AT2R mRNA was analyzed via quantitative RT-PCR, and human umbilical vein endothelial cells (HUVECs) were used as positive control (A). Immunostaining demonstrating co-localization of AT1R and AT2R on the cell membrane of BM-MSCs treated with VEGF-A (2 ng/ml) plus Ang II (2 ng/ml). AT1R stained in red co-localized with AT2R labeled in green to produce a yellow merge (B). One image representative of three independent experiments is shown. Data are representative of three independent experiments performed from three different cultures from swine bone marrow. *P <0.05 vs. naïve MSCs. ^# P <0.05 vs. Ang II-treated MSCs, n = 3. DAPI, 4′,6-diamidino-2-phenylindole.